The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute. This is a special funding opportunity separate from ADDF’s Therapeutic Funding Programs.
NOTE Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).
Deadlines:
- Required Letter of Intent: June 3, 2024, 5:00 PM EDT
- Invited Full Proposal: August 26, 2024, 5:00 PM EDT
The 2024 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly:
- Proteostasis (including autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modification associated with proteostasis, protein folding/misfolding, ER stress, extracellular clearance)
- Senescence (including cells that have halted division, shifted towards a secretory phenotype, altered morphology and epigenetics, and decreased apoptosis)
- Academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada and United Kingdom only are eligible to apply.
- Lead investigator must have an MD, a PhD, or equivalent.
- Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, slow, or reverse Alzheimer’s disease or related dementias (vascular dementia, frontotemporal dementia, Lewy Body dementia, LATE etc).
- Team should possess intellectual property (IP) or have potential for novel IP that has not yet been licensed to a for-profit entity.
- Researchers working on drug development programs that are relevant to but not presently focused on the Alzheimer’s field are strongly encouraged to apply.
The award typically entails up to $600,000 over 2 years with dedicated support for milestone-driven projects from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.